A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship.
anticancer bioactive phytocompounds
cytotoxic agents
neoplastic disease
proliferation
structure activity relationship (SAR)
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
09 May 2022
09 May 2022
Historique:
received:
16
04
2022
revised:
04
05
2022
accepted:
05
05
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
Cancer is a disorder that rigorously affects the human population worldwide. There is a steady demand for new remedies to both treat and prevent this life-threatening sickness due to toxicities, drug resistance and therapeutic failures in current conventional therapies. Researchers around the world are drawing their attention towards compounds of natural origin. For decades, human beings have been using the flora of the world as a source of cancer chemotherapeutic agents. Currently, clinically approved anticancer compounds are vincristine, vinblastine, taxanes, and podophyllotoxin, all of which come from natural sources. With the triumph of these compounds that have been developed into staple drug products for most cancer therapies, new technologies are now appearing to search for novel biomolecules with anticancer activities. Ellipticine, camptothecin, combretastatin, curcumin, homoharringtonine and others are plant derived bioactive phytocompounds with potential anticancer properties. Researchers have improved the field further through the use of advanced analytical chemistry and computational tools of analysis. The investigation of new strategies for administration such as nanotechnology may enable the development of the phytocompounds as drug products. These technologies have enhanced the anticancer potential of plant-derived drugs with the aim of site-directed drug delivery, enhanced bioavailability, and reduced toxicity. This review discusses mechanistic insights into anticancer compounds of natural origins and their structural activity relationships that make them targets for anticancer treatments.
Identifiants
pubmed: 35566385
pii: molecules27093036
doi: 10.3390/molecules27093036
pmc: PMC9102595
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Podophyllotoxin
L36H50F353
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Cancer. 2006 Oct;6(10):789-802
pubmed: 16990856
Mini Rev Med Chem. 2013 Oct;13(12):1769-77
pubmed: 23432381
J Am Chem Soc. 1974 May 29;96(11):3706-8
pubmed: 4833726
Int J Mol Med. 2015 Mar;35(3):771-6
pubmed: 25592869
Chem Pharm Bull (Tokyo). 2004 Jan;52(1):1-26
pubmed: 14709862
Cancer Chemother Pharmacol. 1979;2(4):229-32
pubmed: 455579
Life Sci. 2006 Apr 25;78(22):2550-7
pubmed: 16337242
J Pharmacol Sci. 2013;121(4):272-81
pubmed: 23603895
Cancer Res. 2005 Jun 15;65(12):5399-407
pubmed: 15958589
Eur J Biochem. 2002 May;269(10):2591-600
pubmed: 12027898
Pharmaceuticals (Basel). 2021 Feb 14;14(2):
pubmed: 33673021
Clin Breast Cancer. 2000 Apr;1(1):32-40; discussion 41-2
pubmed: 11899388
Mol Cell. 2011 Jun 24;42(6):731-43
pubmed: 21700220
J Med Chem. 2009 Feb 12;52(3):655-63
pubmed: 19128055
Biochim Biophys Acta. 2009 Dec;1796(2):293-308
pubmed: 19683560
Mol Cancer Ther. 2010 Oct;9(10):2689-99
pubmed: 20937594
Int J Mol Sci. 2017 Mar 17;18(3):
pubmed: 28304343
Molecules. 2020 Apr 20;25(8):
pubmed: 32326113
Anticancer Res. 1992 Sep-Oct;12(5):1459-61
pubmed: 1332578
Oxid Med Cell Longev. 2019 Apr 4;2019:7480512
pubmed: 31089416
Mol Cell Proteomics. 2016 Apr;15(4):1220-31
pubmed: 26711467
Curr Med Chem. 2020;27(27):4567-4576
pubmed: 32175831
Bioorg Med Chem. 2018 Jan 15;26(2):340-355
pubmed: 29269253
Biochim Biophys Acta. 1987 Dec 7;926(3):215-23
pubmed: 3120782
Int J Mol Sci. 2019 Feb 27;20(5):
pubmed: 30818786
Phytochemistry. 2000 May;54(2):115-20
pubmed: 10872202
Biochim Biophys Acta. 2004 Feb 10;1661(1):1-8
pubmed: 14967469
Bioorg Med Chem Lett. 1999 Sep 20;9(18):2731-6
pubmed: 10509925
Chem Biol Interact. 1999 Jul 1;121(2):161-75
pubmed: 10418962
Cancer Res. 1989 Mar 15;49(6):1465-9
pubmed: 2538227
Leukemia. 2002 Nov;16(11):2275-84
pubmed: 12399973
Br J Pharmacol. 2007 Oct;152(3):386-95
pubmed: 17700718
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Semin Oncol. 1996 Apr;23(2 Suppl 5):2-7
pubmed: 8610232
Biol Cell. 1990;68(1):21-9
pubmed: 2180513
Molecules. 2013 Jul 26;18(8):8929-44
pubmed: 23896618
Onco Targets Ther. 2015 Aug 21;8:2209-14
pubmed: 26345293
Eur J Cancer. 1993;29A(6):856-9
pubmed: 8484977
Nat Prod Res. 2016;30(4):373-85
pubmed: 25813519
Cancer Biol Ther. 2002 Sep-Oct;1(5):453-8
pubmed: 12496469
Pharmacol Ther. 1991 Oct;52(1):35-84
pubmed: 1687171
Anticancer Res. 2003 Jan-Feb;23(1A):363-98
pubmed: 12680238
Mol Pharmacol. 2001 Oct;60(4):785-9
pubmed: 11562441
Lung Cancer. 1994 Dec;11(5-6):385-91
pubmed: 7704495
N Engl J Med. 1974 Oct 31;291(18):932-4
pubmed: 4606109
Curr Pharm Des. 2015;21(38):5501-17
pubmed: 26429715
Curr Med Chem. 2006;13(17):2021-39
pubmed: 16842195
Molecules. 2017 Feb 28;22(3):
pubmed: 28264528
Pharmaceuticals (Basel). 2021 Aug 24;14(9):
pubmed: 34577537
Zhongguo Yao Li Xue Bao. 1999 Apr;20(4):297-302
pubmed: 10452112
Colloids Surf B Biointerfaces. 2021 Jan;197:111404
pubmed: 33142257
J Mol Biol. 2009 May 29;389(1):146-56
pubmed: 19362093
Cancer Lett. 2005 Jun 8;223(2):293-301
pubmed: 15896464
Cancer Res. 1960 Aug;20:1016-22
pubmed: 14407465
J Biol Chem. 1995 Jun 23;270(25):14998-5004
pubmed: 7797481
Anticancer Res. 2013 May;33(5):1819-27
pubmed: 23645726
J Nat Prod. 2007 Mar;70(3):461-77
pubmed: 17309302
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8
pubmed: 21205897
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):380-6
pubmed: 15667956
J Nat Prod. 2004 Feb;67(2):269-72
pubmed: 14987068
Eur J Biochem. 1997 Jan 15;243(1-2):527-36
pubmed: 9030781
Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17
pubmed: 12678749
Biochem Biophys Res Commun. 1985 May 16;128(3):1239-46
pubmed: 4004859
Oncology. 1995 Jan-Feb;52(1):86-7
pubmed: 7800350
Curr Pharm Des. 2013;19(11):2032-46
pubmed: 23116311
Clin Cancer Res. 2008 Mar 15;14(6):1625-32
pubmed: 18347163
Acta Pharmacol Sin. 2009 Feb;30(2):202-8
pubmed: 19122671
Chem Soc Rev. 2010 Feb;39(2):435-54
pubmed: 20111769
J Med Chem. 2008 Sep 11;51(17):5229-42
pubmed: 18698753
Antioxidants (Basel). 2020 Mar 27;9(4):
pubmed: 32230703
Int J Prev Med. 2013 Nov;4(11):1231-5
pubmed: 24404355
Life Sci. 1987 Jan 5;40(1):35-9
pubmed: 3796211
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
pubmed: 18628464
Bioconjug Chem. 2010 Jan;21(1):84-92
pubmed: 19891424
Cell Biol Toxicol. 2007 Sep;23(5):337-54
pubmed: 17447015
Int J Cancer. 1990 Aug 15;46(2):262-6
pubmed: 2200754
Molecules. 2017 Oct 10;22(10):
pubmed: 28994736
Curr Med Chem Anticancer Agents. 2005 Mar;5(2):173-82
pubmed: 15777224
Curr Pharm Des. 2002;8(27):2505-20
pubmed: 12369944
Childs Nerv Syst. 2013 Oct;29(10):1851-8
pubmed: 23748464
Adv Drug Deliv Rev. 2011 Jul 18;63(8):568-81
pubmed: 21664937
J Clin Oncol. 2009 Sep 20;27(27):4454-61
pubmed: 19687335
Front Pharmacol. 2021 Nov 08;12:732891
pubmed: 34819855
J Ethnopharmacol. 2014 Feb 12;151(3):1040-1055
pubmed: 24362078
Curr Med Chem. 2014;21(5):575-91
pubmed: 24059226
P T. 2015 Mar;40(3):191-205
pubmed: 25798040
J Nat Prod. 1991 Mar-Apr;54(2):632-7
pubmed: 1919593
Rev Neurosci. 2015;26(4):371-83
pubmed: 25879319
Expert Opin Drug Saf. 2011 Jul;10(4):645-53
pubmed: 21524237
Eur J Biochem. 1977 Jan;72(2):323-30
pubmed: 319998
Fundam Clin Pharmacol. 2017 Feb;31(1):54-63
pubmed: 27521287
Mol Pharmacol. 1989 Sep;36(3):366-70
pubmed: 2571072
J Med Chem. 1997 Mar 14;40(6):961-6
pubmed: 9083485
Bioorg Med Chem. 1994 Dec;2(12):1397-402
pubmed: 7788302
Cancer Res. 1989 Sep 15;49(18):5077-82
pubmed: 2548710
Oncogene. 2008 Jan 10;27(3):285-99
pubmed: 17700538
Biochim Biophys Acta. 2002 Dec 23;1567(1-2):49-55
pubmed: 12488037
J Electron Microsc (Tokyo). 1983;32(2):115-24
pubmed: 6315848
Clin Cancer Res. 2001 May;7(5):1452-8
pubmed: 11350917
Mol Cancer Ther. 2008 Sep;7(9):2713-24
pubmed: 18790752
Mol Pharmacol. 1975 Sep;11(5):511-9
pubmed: 1237080
Cancer Chemother Pharmacol. 2006 Jan;57(2):145-54
pubmed: 16001167
J Am Chem Soc. 1971 May 5;93(9):2325-7
pubmed: 5553076
Expert Opin Drug Discov. 2009 Nov;4(11):1099-111
pubmed: 23480431
Biochem Pharmacol. 2001 Sep 15;62(6):733-41
pubmed: 11551518
J Biol Chem. 2017 Apr 28;292(17):6938-6951
pubmed: 28264934
J Biol Chem. 2010 Sep 10;285(37):28883-92
pubmed: 20551329
Science. 1985 Jun 7;228(4704):1154-60
pubmed: 3890182
Biomaterials. 2007 Nov;28(31):4673-83
pubmed: 17688940
Bioorg Med Chem. 2010 Aug 1;18(15):5634-46
pubmed: 20615710
Zhongguo Zhong Yao Za Zhi. 2009 Jul;34(14):1840-4
pubmed: 19894521
Hematology. 2004 Aug;9(4):259-70
pubmed: 15621733
Anticancer Drugs. 2014 Apr;25(4):462-71
pubmed: 24500030
Biomedicines. 2018 Mar 26;6(2):
pubmed: 29587429
Postepy Hig Med Dosw (Online). 2014 Oct 23;68:1216-24
pubmed: 25380204
Cancer Res. 2010 Dec 15;70(24):10192-201
pubmed: 21159641
Phytochemistry. 2021 Jul;187:112769
pubmed: 33887559
Molecules. 2016 Aug 17;21(8):
pubmed: 27548121
Biochem Pharmacol. 1975 Sep 15;24(18):1735-8
pubmed: 1238093
Planta Med. 1985 Dec;51(6):545-6
pubmed: 17345297
Biomolecules. 2021 Jul 14;11(7):
pubmed: 34356649
Mol Cancer Ther. 2014 Feb;13(2):275-84
pubmed: 24435445
J Med Chem. 2006 Oct 19;49(21):6412-5
pubmed: 17034147
Anticancer Drugs. 2001 Jan;12(1):51-6
pubmed: 11272286
Molecules. 2017 Aug 01;22(8):
pubmed: 28763044
Cancer Chemother Pharmacol. 1982;7(2-3):73-80
pubmed: 7044593
Pharmacol Ther. 1991;51(2):257-67
pubmed: 1784631
Int J Mol Sci. 2018 Nov 09;19(11):
pubmed: 30423952
Bioorg Med Chem. 2006 Apr 15;14(8):2810-5
pubmed: 16412648
Br J Cancer. 2006 Aug 7;95(3):253-9
pubmed: 16847470
Anticancer Res. 1999 Mar-Apr;19(2A):1037-42
pubmed: 10368652
Eur J Med Chem. 2018 Jan 20;144:797-816
pubmed: 29291446
Org Biomol Chem. 2003 Sep 7;1(17):3033-7
pubmed: 14518125
Cancer Lett. 2009 Dec 28;286(2):232-9
pubmed: 19541408
Angew Chem Int Ed Engl. 2016 Aug 22;55(35):10210-26
pubmed: 27488942
BMC Complement Med Ther. 2020 Jul 20;20(1):227
pubmed: 32690087
Am J Clin Oncol. 1994 Jun;17(3):242-5
pubmed: 8192111
Molecules. 2015 Feb 12;20(2):2973-3000
pubmed: 25685907
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900
pubmed: 11712783
J Med Chem. 1991 Jan;34(1):98-107
pubmed: 1846923
Bioorg Med Chem Lett. 2018 Sep 15;28(17):2816-2826
pubmed: 30122223
Biochemistry. 1989 May 30;28(11):4629-38
pubmed: 2548584
Biol Chem. 1997 Sep;378(9):989-96
pubmed: 9348108
J Med Chem. 2005 Jun 16;48(12):4087-99
pubmed: 15943482
Nat Rev Cancer. 2004 Apr;4(4):253-65
pubmed: 15057285
Molecules. 2011 May 24;16(5):4295-304
pubmed: 21610658
Pharmacogn Rev. 2016 Jul-Dec;10(20):90-99
pubmed: 28082790
Theranostics. 2017 Aug 11;7(14):3415-3431
pubmed: 28912885
Urol Oncol. 2002 Jul-Aug;7(4):159-66
pubmed: 12474532
Front Biosci (Schol Ed). 2012 Jan 01;4(1):142-56
pubmed: 22202049
Life Sci. 2013 Sep 3;93(8):323-8
pubmed: 23871804
Med Trop (Mars). 2006 Dec;66(6):602-5
pubmed: 17286032
JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):898-905
pubmed: 27389786
Bull Cancer. 1981;68(5):437-41
pubmed: 7037078
Biochem Pharmacol. 1973 Sep 1;22(17):2141-50
pubmed: 4733669
J Exp Clin Cancer Res. 2009 Jun 11;28:79
pubmed: 19519890
J Med Chem. 2013 Feb 14;56(3):625-7
pubmed: 23316748
FEBS Lett. 1977 Mar 15;75(1):159-62
pubmed: 852577
Exp Mol Pathol. 2007 Feb;82(1):25-32
pubmed: 17081516
J Med Chem. 2005 Jan 27;48(2):556-68
pubmed: 15658869
Science. 1975 Sep 19;189(4207):1002-5
pubmed: 1241159